Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.
Sebastiano Bruno SolerteFrancesca D'AddioRoberto TrevisanElisabetta LovatiAntonio RossiIda PastoreMarco Dell'AcquaElio IppolitoCristiana ScarannaRosalia BellanteSilvia GallianiAlessandro Roberto DodesiniGiuseppe LeporeFrancesca GeniRoberta Maria FiorinaEmanuele CatenaAngelo CorsicoRiccardo ColomboMarco MiraniCarlo De RivaSalvatore Endrio OleandriReza AbdiJoseph V BonventreStefano RusconiFranco FolliAntonio Di SabatinoGianvincenzo ZuccottiMassimo GalliPaolo FiorinaPublished in: Diabetes care (2020)
In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.